{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T03:36:53Z","timestamp":1774064213143,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Stiftung f\u00fcr Rheumaforschung"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13075-016-0969-2","type":"journal-article","created":{"date-parts":[[2016,3,21]],"date-time":"2016-03-21T20:42:43Z","timestamp":1458592963000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort"],"prefix":"10.1186","volume":"18","author":[{"name":"on behalf of the Rheumatologists of Swiss Clinical Quality Management Program for Axial Spondyloarthritis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Ciurea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Exer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Tamborrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Steininger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf O.","family":"Kissling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrg","family":"Bernhard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almut","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,22]]},"reference":[{"key":"969_CR1","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/art.20852","volume":"52","author":"D Heijde van der","year":"2005","unstructured":"van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52:582\u201391.","journal-title":"Arthritis Rheum."},{"key":"969_CR2","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1136\/ard.2004.035105","volume":"64","author":"JC Davis","year":"2005","unstructured":"Davis JC, van der Heijde D, Braun J, Dougados M, Cush J, Clegg D, et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96\u00a0weeks. Ann Rheum Dis. 2005;64:1557\u201362.","journal-title":"Ann Rheum Dis."},{"key":"969_CR3","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D Heijde van der","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54:2136\u201346.","journal-title":"Arthritis Rheum."},{"key":"969_CR4","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","volume":"58","author":"RD Inman","year":"2008","unstructured":"Inman RD, Davis Jr JC, van der Heijde D, Diekman L, Sieper J, Kim SI, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum. 2008;58:3402\u201312.","journal-title":"Arthritis Rheum."},{"key":"969_CR5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","volume":"73","author":"R Landew\u00e9","year":"2014","unstructured":"Landew\u00e9 R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study. Ann Rheum Dis. 2014;73:39\u201347.","journal-title":"Ann Rheum Dis."},{"key":"969_CR6","doi-asserted-by":"crossref","first-page":"e000017","DOI":"10.1136\/rmdopen-2014-000017","volume":"1","author":"JR Maneiro","year":"2015","unstructured":"Maneiro JR, Souto A, Salgado E, Mera A, Gomez-Reino JJ. Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis. RMD Open. 2015;1:e000017.","journal-title":"RMD Open."},{"key":"969_CR7","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/ard.2010.147744","volume":"70","author":"N Vastesaeger","year":"2011","unstructured":"Vastesaeger N, van der Heijde D, Inman RD, Wang Y, Deodhar A, Hsu B, et al. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis. 2011;70:973\u201381.","journal-title":"Ann Rheum Dis."},{"key":"969_CR8","author":"A Ciurea","year":"2015","unstructured":"Ciurea A, Scherer A, Weber U, Exer P, Bernhard J, Tamborrini G, et al. Impaired response to treatment with tumour necrosis factor \u03b1 inhibitors in smokers with axial spondyloarthritis. Ann Rheum Dis. 2015. doi: 10.1136\/annrheumdis-2013-205133 .","journal-title":"Ann Rheum Dis"},{"key":"969_CR9","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar1881","volume":"8","author":"JJ Gomez-Reino","year":"2006","unstructured":"Gomez-Reino JJ, Carmona L, BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther. 2006;8:R29.","journal-title":"Arthritis Res Ther"},{"key":"969_CR10","first-page":"2183","volume":"32","author":"C Delaunay","year":"2005","unstructured":"Delaunay C, Farrenq V, Marini-Portugal A, Cohen JD, Chevalier X, Claudepierre P. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. J Rheumatol. 2005;32:2183\u20135.","journal-title":"J Rheumatol."},{"key":"969_CR11","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/art.22236","volume":"55","author":"F Cantini","year":"2006","unstructured":"Cantini F, Niccoli L, Benucci M, Chindamo D, Nannini C, Olivieri I, et al. Switching from infliximab to once-weekly administration of 50\u00a0mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study. Arthritis Rheum. 2006;55:812\u20136.","journal-title":"Arthritis Rheum."},{"key":"969_CR12","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/ard.2007.073569","volume":"66","author":"F Conti","year":"2007","unstructured":"Conti F, Ceccarelli F, Marocchi E, Magrini L, Spinelli FR, Spadaro A, et al. Switching tumour necrosis factor \u03b1 antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis. 2007;66:1393\u20137.","journal-title":"Ann Rheum Dis."},{"key":"969_CR13","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/rheumatology\/ken334","volume":"47","author":"DJ Pradeep","year":"2008","unstructured":"Pradeep DJ, Keat AC, Gaffney K, Brooksby A, Leeder J, Harris C. Switching anti-TNF therapy in ankylosing spondylitis. Rheumatology (Oxford). 2008;47:1726\u20137.","journal-title":"Rheumatology (Oxford)"},{"key":"969_CR14","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/rheumatology\/ken094","volume":"47","author":"LC Coates","year":"2008","unstructured":"Coates LC, Cawkwell LS, Ng NW, Bennett AN, Bryer DJ, Fraser AD, et al. Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. Rheumatology (Oxford). 2008;47:897\u2013900.","journal-title":"Rheumatology (Oxford)"},{"key":"969_CR15","doi-asserted-by":"crossref","first-page":"R117","DOI":"10.1186\/ar3054","volume":"12","author":"M Rudwaleit","year":"2010","unstructured":"Rudwaleit M, Van den Bosch F, Kron M, Kary S, Kupper H. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther. 2010;12:R117.","journal-title":"Arthritis Res Ther."},{"key":"969_CR16","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1093\/rheumatology\/keq008","volume":"49","author":"A Spadaro","year":"2010","unstructured":"Spadaro A, Punzi L, Marchesoni A, Lubrano E, Mathieu A, Cantini F, et al. Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study. Rheumatology (Oxford). 2010;49:1107\u201311.","journal-title":"Rheumatology (Oxford)"},{"key":"969_CR17","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s10354-010-0795-0","volume":"160","author":"G Haberhauer","year":"2010","unstructured":"Haberhauer G, Strehblow C, Fasching P. Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis. Wien Med Wochenschr. 2010;160:220\u20134.","journal-title":"Wien Med Wochenschr."},{"key":"969_CR18","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/ard.2010.131797","volume":"70","author":"E Lie","year":"2011","unstructured":"Lie E, van der Heijde D, Uhlig T, Mikkelsen K, Rodevand E, Koldingsnes W, et al. Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann Rheum Dis. 2011;70:157\u201363.","journal-title":"Ann Rheum Dis."},{"key":"969_CR19","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/rheumatology\/keq377","volume":"50","author":"J Paccou","year":"2011","unstructured":"Paccou J, Solau-Gervais E, Houvenagel E, Salleron J, Luraschi H, Philippe P, et al. Efficacy in current practice of switching between anti-tumour necrosis factor-\u03b1 agents in spondyloarthropathies. Rheumatology (Oxford). 2011;50:714\u201320.","journal-title":"Rheumatology (Oxford)"},{"key":"969_CR20","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1186\/ar4258","volume":"15","author":"C Plasencia","year":"2013","unstructured":"Plasencia C, Pascual-Salcedo D, Garcia-Carazo S, Lojo L, Nuno L, Villalba A, et al. The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients. Arthritis Res Ther. 2013;15:R79.","journal-title":"Arthritis Res Ther."},{"key":"969_CR21","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/rheumatology\/ket249","volume":"52","author":"A Spadaro","year":"2013","unstructured":"Spadaro A, Lubrano E, Marchesoni A, D\u2019Angelo S, Ramonda R, Addimanda O, et al. Remission in ankylosing spondylitis treated with anti-TNF-\u03b1 drugs: a national multicentre study. Rheumatology (Oxford). 2013;52:1914\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"969_CR22","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1136\/annrheumdis-2012-201933","volume":"72","author":"B Glintborg","year":"2013","unstructured":"Glintborg B, Ostergaard M, Krogh NS, Tarp U, Manilo N, Loft AG, et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor \u03b1 inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis. 2013;72:1149\u201355.","journal-title":"Ann Rheum Dis."},{"issue":"Suppl 1","key":"969_CR23","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1007\/s10198-014-0598-0","volume":"15","author":"K Gulyas","year":"2014","unstructured":"Gulyas K, Bodnar N, Nagy Z, Szamosi S, Horvath A, Vancsa A, et al. Real-life experience with switching TNF-\u03b1 inhibitors in ankylosing spondylitis. Eur J Health Econ. 2014;15 Suppl 1:S93\u2013100.","journal-title":"Eur J Health Econ."},{"key":"969_CR24","doi-asserted-by":"crossref","first-page":"862969","DOI":"10.1155\/2014\/862969","volume":"2014","author":"M Fabbroni","year":"2014","unstructured":"Fabbroni M, Cantarini L, Caso F, Costa L, Pagano VA, Frediani B, et al. Drug retention rates and treatment discontinuation among anti-TNF-\u03b1 agents in psoriatic arthritis and ankylosing spondylitis in clinical practice. Mediators Inflamm. 2014;2014:862969.","journal-title":"Mediators Inflamm."},{"key":"969_CR25","first-page":"96","volume":"29","author":"A Remy","year":"2011","unstructured":"Remy A, Avouac J, Gossec L, Combe B. Clinical relevance of switching to a second tumour necrosis factor-\u03b1 inhibitor after discontinuation of a first tumour necrosis factor-\u03b1 inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. Clin Exp Rheumatol. 2011;29:96\u2013103.","journal-title":"Clin Exp Rheumatol."},{"key":"969_CR26","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/annrheumdis-2013-204714","volume":"74","author":"K Chatzidionysiou","year":"2015","unstructured":"Chatzidionysiou K, Askling J, Eriksson J, Kristensen LE, van Vollenhoven R, ARTIS group. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register. Ann Rheum Dis. 2015;74:890\u20136.","journal-title":"Ann Rheum Dis"},{"key":"969_CR27","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","volume":"382","author":"D Baeten","year":"2013","unstructured":"Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382:1705\u201313.","journal-title":"Lancet."},{"key":"969_CR28","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","volume":"73","author":"D Poddubnyy","year":"2014","unstructured":"Poddubnyy D, Hermann KG, Callhoff J, Listing J, Sieper J. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis. 2014;73:817\u201323.","journal-title":"Ann Rheum Dis."},{"key":"969_CR29","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/annrheumdis-2012-201915","volume":"72","author":"E Pathan","year":"2013","unstructured":"Pathan E, Abraham S, Van Rossen E, Withrington R, Keat A, Charles PJ, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann Rheum Dis. 2013;72:1475\u201380.","journal-title":"Ann Rheum Dis."},{"key":"969_CR30","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.38140","volume":"65","author":"A Ciurea","year":"2013","unstructured":"Ciurea A, Scherer A, Exer P, Bernhard J, Dudler J, Beyeler B, et al. Tumor necrosis factor-\u03b1 inhibition in radiographic and non-radiographic axial spondyloarthritis: results from a large observational cohort. Arthritis Rheum. 2013;65:3096\u2013106.","journal-title":"Arthritis Rheum."},{"issue":"Suppl 2","key":"969_CR31","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/ard.2008.104018","volume":"68","author":"J Sieper","year":"2009","unstructured":"Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68 Suppl 2:ii1\u201344.","journal-title":"Ann Rheum Dis"},{"key":"969_CR32","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/ard.2011.151563","volume":"70","author":"D Heijde van der","year":"2011","unstructured":"van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landew\u00e9 R, et al. Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70:905\u20138.","journal-title":"Ann Rheum Dis."},{"key":"969_CR33","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/art.30223","volume":"63","author":"J Braun","year":"2011","unstructured":"Braun J, van der Horst-Bruinsma IE, Huang F, Burgos-Vargas R, Vlahos B, Koenig AS, et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum. 2011;63:1543\u201351.","journal-title":"Arthritis Rheum."},{"key":"969_CR34","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/rheumatology\/41.11.1280","volume":"41","author":"M Breban","year":"2002","unstructured":"Breban M, Vignon E, Claudepierre P, Devauchelle V, Wendling D, Lespessailles E, et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology (Oxford). 2002;41:1280\u20135.","journal-title":"Rheumatology (Oxford)"},{"key":"969_CR35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/ard.2010.138594","volume":"70","author":"P Machado","year":"2011","unstructured":"Machado P, Landew\u00e9 R, Lie E, Kvien TK, Braun J, Baker D, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011;70:47\u201353.","journal-title":"Ann Rheum Dis."},{"key":"969_CR36","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","volume":"44","author":"JJ Anderson","year":"2001","unstructured":"Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum. 2001;44:1876\u201386.","journal-title":"Arthritis Rheum."},{"key":"969_CR37","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/art.38921","volume":"67","author":"P Machado","year":"2015","unstructured":"Machado P, Navarro-Compan V, Landew\u00e9 R, van Gaalen FA, Roux C, van der Heijde D. Calculating the Ankylosing Spondylitis Disease Activity Score if the conventional C-reactive protein level is below the limit of detection or if high-sensitivity c-reactive protein is used: an analysis in the DESIR cohort. Arthritis Rheumatol. 2015;67:408\u201313.","journal-title":"Arthritis Rheumatol."},{"key":"969_CR38","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/ard.2008.105064","volume":"69","author":"A Finckh","year":"2010","unstructured":"Finckh A, Ciurea A, Brulhart L, Moller B, Walker UA, Courvoisier D, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis. 2010;69:387\u201393.","journal-title":"Ann Rheum Dis."},{"issue":"6 Suppl 74","key":"969_CR39","first-page":"24","volume":"30","author":"E Roussou","year":"2012","unstructured":"Roussou E, Ciurtin C. Clinical overlap between fibromyalgia tender points and enthesitis sites in patients with spondyloarthritis who present with inflammatory back pain. Clin Exp Rheumatol. 2012;30(6 Suppl 74):24\u201330.","journal-title":"Clin Exp Rheumatol"},{"issue":"6 Suppl 63","key":"969_CR40","first-page":"S33","volume":"28","author":"R Almodovar","year":"2010","unstructured":"Almodovar R, Carmona L, Zarco P, Collantes E, Gonzalez C, Mulero J, et al. Fibromyalgia in patients with ankylosing spondylitis: prevalence and utility of the measures of activity, function and radiological damage. Clin Exp Rheumatol. 2010;28(6 Suppl 63):S33\u20139.","journal-title":"Clin Exp Rheumatol"},{"key":"969_CR41","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00296-014-2955-9","volume":"34","author":"F Salaffi","year":"2014","unstructured":"Salaffi F, De Angelis R, Carotti M, Gutierrez M, Sarzi-Puttini P, Atzeni F. Fibromyalgia in patients with axial spondyloarthritis: epidemiological profile and effect on measures of disease activity. Rheumatol Int. 2014;34:1103\u201310.","journal-title":"Rheumatol Int."},{"issue":"8","key":"969_CR42","doi-asserted-by":"crossref","first-page":"e105193","DOI":"10.1371\/journal.pone.0105193","volume":"9","author":"A Fisher","year":"2014","unstructured":"Fisher A, Bassett K, Wright JM, Brookhart MA, Freeman H, Dormuth CR. Comparative persistence of the TNF antagonists in rheumatoid arthritis \u2013 a population-based cohort study. PLoS One. 2014;9(8):e105193.","journal-title":"PLoS One"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-016-0969-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T16:43:52Z","timestamp":1567701832000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.com\/content\/18\/1\/71"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,22]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["969"],"URL":"https:\/\/doi.org\/10.1186\/s13075-016-0969-2","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,22]]},"article-number":"71"}}